Conservative treatment modalities and outcomes for osteoarthritis: The concomitant pyramid of treatment

Physician and Sportsmedicine

Volumn 38, Issue 2, 2010, Pages 133-145

  Langworthy, Michael J ^a   Saad, Amira ^b   Langworthy, Nadia M ^c  

^a Battle Creek Orthopaedics and Sports Medicine Clinic   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Conservative treatment; Exercise; Hyaluronic acid; Multimodal therapy; NSAIDs; Nutraceuticals; Osteoarthritis; Physical therapy; Viscosupplements; Weight loss

Indexed keywords

ACETYLSALICYLIC ACID; CAPSAICIN; CELECOXIB; CHONDROITIN SULFATE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOSAMINE; HYALURONIC ACID; IBUPROFEN; LIDOCAINE; METHYLPREDNISOLONE; NAPROXEN; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRACEUTICAL; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALICYLIC ACID; SEROTONIN UPTAKE INHIBITOR; STEROID; TRAMADOL; TRIAMCINOLONE HEXACETONIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D;

ACUPUNCTURE; ALGORITHM; ARTHRALGIA; ARTHRITIS; BRACE; BURNING SENSATION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; ELECTROSTIMULATION; EXERCISE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIP OSTEOARTHRITIS; HIP PAIN; HUMAN; INTESTINE PERFORATION; JOINT FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; NEPHROTOXICITY; NONHUMAN; OINTMENT; OSTEOARTHRITIS; PAIN; PHYSIOTHERAPY; PRURITUS; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; ULCER; WEIGHT REDUCTION; INTRAARTICULAR DRUG ADMINISTRATION; KNEE; TREATMENT OUTCOME;

HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; KNEE JOINT; OSTEOARTHRITIS, KNEE; PHYSICAL THERAPY MODALITIES; TREATMENT OUTCOME;

EID: 77955356547     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2010.06.1792     Document Type: Review

References (102)

1. Felson DT, Zhang Y. An update an the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41(8):1343-1355.
2. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(1):226-229.
3. Buckwalter JA, Lappin DR. The disproportionate impact of chronic arthralgia and arthritis among women. Clin Orthop Relat Res. 2000;372:159-168.
4. Langworthy MJ, Nelson F, Coutts R. The basic science of cartilage. In: Cole BJ, Malek MM, eds. Articular Cartilage Lesions. New York, NY: Springer; 2004:1-11.
5. Kraus VG. Pathogenesis and treatment of osteoarthritis. Med Clin North Am. 1997;81(1):85-112.
6. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89(4):780-785.
7. DeGroot J, Verzijl N, Jacobs KM, et al. Accumulation of advanced glycation endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage. 2001;9(8)-720-726.
8. Barbero A, Grogan S, Schäfer D, Heberer M, Mainil-Varlet P, Martin I. Age related changes in human articular chondrocyte yield, proliferation and post-expansion chondrogenic capacity. Osteoarthritis Cartilage. 2004;12(6):476-484.
9. Claassen H, Hassenpflug J, Schünke M, Sierralta W, Thole H, Kurz B. Immunohistochemical detection of estrogen receptor alpha in articular chondrocytes from cows, pigs and humans: in situ and in vitro results. Ann Anat. 2001;183(3):223-227.
10. DeGroot J, Verzijl N, Jacobs KM, et al. Accumulation of advanced glycation end products reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage. 2001;9(8):720-726. (Pubitemid 33076763)
11. Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg. 2000;8(5):277-284.
12. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med. 1992;116(7):535-539.
13. Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med. 1997;127(2):97-104.
14. Ettinger WH Jr, Burns R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA. 1997;277(1):25-31.
15. Creamer P, Hochberg MC. Osteoarthritis. Lancet. 1997;350(9076):503-508.
16. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43(9):1905-1915.
17. Krenzelok EP. The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol (Phila). 2009;47(8):784-789.
18. Devos-Comby L, Cronan T, Roesch SC. Do exercise and self-management interventions benefit patients with osteoarthritis of the knee? A metaanalytic review. J Rheumatol. 2006;33(4):744-756.
19. Woodcock J. A difficult balance - pain management, drug safety, and the FDA. N Engl J Med. 2009;361(22):2105-2107.
20. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18-24.
21. Goldstein JL, Aisenberg J, Lanza F, et al. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. Clin Ther. 2006;28(3):340-351.
22. Hollenz M, Stolte M, Leodolter A, Labenz J. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis. 2006;24(1-2):189-194.
23. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340(24): 1888-1899.
24. Hunt RH, Lanas A, Stichtenoth DO, Scarpignato C. Myths and facts in the use of anti-inflammatory drugs [published online ahead of print May 8, 2009]. Ann Med.
25. Lanas A, Perez-Aisa MA, Feu F, et al; Investigators of the Asociación Española de Gastroenterología (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. GI related mortality and nsaid use. Am J Gastroenterol. 2005;100(8):1685-1693.
26. Urban MK. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs. Orthopedics. 2000;23(7 suppl):S761-S764.
27. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta analysis. Ann Intern Med. 1991;115(10):787-796.
28. Hollenz M, Stolte M, Leodolter A, Labenz J. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis. 2006;24(1-2):189-194.
29. Neumaier J. Therapy of joint pain in arthrosis and arthritis. Classical nonsteroidal anti-inflammatory agents, coxibs - or opioids? [in German]. MMW Fortschr Med. 2009;151(34-35):22-23.
30. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282(20): 1921-1928.
31. Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford). 2003;42(11): 1332-1341. (Pubitemid 37407025)
32. White WB. Cyclooxygenase-2 inhibitors and cardiovascular thromboembolic events. J Am Coll Cardiol. 2002;40(3):577-578.
33. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8(2):85-95.
34. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068-2073.
35. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99(1):91-98.
36. Dahners LE, Mullis BH. Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing. J Am Acad Orthop Surg. 2004;12(3):139-143.
37. Vielpeau C, Joubert JM, Hulet C. Naproxen in the prevention of heterotopic ossification after total hip replacement. Clin Orthop Relat Res. 1999;(369):279-288.
38. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282(20):1929-1933.
39. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med. 2003;253(6):643-652.
40. Goodwin JL, Kraemer JJ, Bajwa ZH. The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr Rheumatol Rep. 2009;11(1):5-14.
41. Tramodol hydrochloride. In: Physicians' Desk Reference. Ed 64. Montvale, NJ: PDR Network, LLC; 2009:2813-2817.
42. Pyne D, Ioannou Y, Mootoo R, Bhanji A. Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Clin Rheumatol. 2004;23(2):116-120.
43. Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2003;48(2):370-377.
44. Fubini SL, Todhunter RJ, Burton-WursterN, Vernier-Singer M, MacLeod JN. Corticosteroids alter the differentiated phenotype of articular chondrocytes. J Orthop Res. 2001;19(4): 688-695.
45. Genovese MC. Joint and soft-tissue injection. A useful adjuvant to systemic and local treatment. Postgrad Med. 1998;103(2):125-134.
46. Lippiello L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res. 2000;381:229-240.
47. Piperno M, Reboul P, Hellio Le Graverand MP, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage. 2000;8(3):207-212.
48. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808.
49. Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. 2002;51(5):425-430.
50. Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet. 1998;35(5):347-359.
51. Lualdi P. Bioavailability of oral chondroitin sulfate. Rheumatol Int. 1993; 13(1):39-43.
52. Parnham MJ. Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. Biochem Pharmacol. 1999;58(2):209-215.
53. Mills SY, Jacoby RK, Chacksfield M, Willoughby M. Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: a doubleblind study. Br J Rheumatol. 1996;35(9):874-878.
54. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallo-catechin- 3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med. 2002;33(8):1097-1105.
55. Baker W. Vitamin D. Bone benefits and beyond. Mayo Clin Health Lett. 2009;27(9):4-5.
56. Felson DT, Niu J, Clancy M, et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum. 2007;56(1): 129-136.
57. Herrmann G, Steeger D, Klasser M, et al. Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac. Clin Rheumatol. 2000; 19(2): 99-104.
58. Bliddal H, Rosetzsky A, Schlichting P, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage. 2000;8(1):9-12.
59. Goldberg H, Avins A, Bent S. Chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007; 147(12):883.
60. Ramsey DK, Briem K, Axe MJ, Snyder-Mackler L. A mechanical theory for the effectiveness of bracing for medial compartment osteoarthritis of the knee. J Bone Joint Surg Am. 2007;89(11):2398-2407. (Pubitemid 350086328)
61. Barnes CL, Cawley PW, Hederman B. Effect of Counter Force brace on symptomatic relief in a group of patients with symptomatic unicompartmental osteoarthritis: a prospective 2-year investigation. Am J Orthop (Belle Mead NJ). 2002;31(7):396-401.
62. Polio FE, Otis JC, Backus SI, Warren RF, Wickiewicz TL. Reduction of medial compartment loads with valgus bracing of the osteoarthritic knee. Am J Sports Med. 2002;30(3):414-421.
63. Giori NJ. Load-shifting brace treatment for osteoarthritis of the knee: a minimum 2 1/2-year follow-up study. J Rehabil Res Dev. 2004;41(2): 187-194.
64. Kerrigan DC, Lelas JL, Goggins J, Merriman GJ, Kaplan RJ, Felson DT. Effectiveness of a lateral-wedge insole on knee varus torque in patients with knee osteoarthritis. Arch Phys Med Rehabil. 2002;83(7):889-893.
65. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
66. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238-245.
67. Selfe TK, Taylor AG. Acupuncture and osteoarthritis of the knee: a review of randomized, controlled trials. Fam Community Health. 2008;31(3):247-254.
68. Ezzo J, Hadhazy V, Birch S, et al. Acupuncture for osteoarthritis of the knee: a systematic review. Arthritis Rheum. 2001;44(4):819-825. (Pubitemid 32319774)
69. Brighton CT, Unger AS, Stambough JL. In vitro growth of bovine articular cartilage chondrocytes in various capacitively coupled electrical fields. J Orthop Res. 1984;2(1):15-22.
70. Zizic TM, Hoffman KC, Holt PA, et al. The treatment of osteoarthritis of the knee with pulsed electrical stimulation. J Rheumatol. 1995;22(9): 1757-1761.
71. Minns Lowe CJ, Barker KL, Dewey ME, Sackley CM. Effectiveness of physiotherapy exercise following hip arthroplasty for osteoarthritis: a systematic review of clinical trials. BMC Musculoskelet Disord. 2009; 10:98.
72. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. Cochrane Database Syst Rev. 2009;(3):CD007912.
73. Fransen M, McConnell S. Land-based exercise for osteoarthritis of the knee: a metaanalysis of randomized controlled trials. J Rheumatol. 2009;36(6):1109-1117.
74. Edmonds S. Therapeutic targets for osteoarthritis. Maturitas. 2009; 63(3):191-194.
75. Hochberg MC, Perlmutter DL, Hudson JI, Altman RD. Preferences in the management of osteoarthritis of the hip and knee: results of a survey of community-based rheumatologists in the United States. Arthritis Care Res. 1996;9(3):170-176.
76. Fransen M, McConnell S. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev. 2008;(4):CD004376.
77. Lange AK, Vanwanseele B, Fiatarone Singh MA. Strength training for treatment of osteoarthritis of the knee: a systematic review. Arthritis Rheum. 2008;59(10): 1488-1494.
78. Hernández-Molina G, Reichenbach S, Zhang B, Lavalley M, Felson DT. Effect of therapeutic exercise for hip osteoarthritis pain: results of a meta-analysis. Arthritis Rheum. 2008;59(9):1221-1228.
79. Blackham J, Garry JP, Cummings DM, Russell RG, Dealleaume L. Does regular exercise reduce the pain and stiffness of osteoarthritis? J Fam Pract. 2008;57(7):476-477.
80. Delarue Y, de Branche B, Anract P, Revel M, Rannou F. Supervised or unsupervised exercise for the treatment of hip and knee osteoarthritis. Clinical practice recommendations. Ann Readapt Med Phys. 2007;50(9):759-768.
81. Tiffreau V, Mulleman D, Coudeyre E, Lefevre-Colau MM, Revel M, Rannou F. The value of individual or collective group exercise programs for knee or hip osteoarthritis. Clinical practice recommendations. Ann Readapt Med Phys. 2007; 50(9): 734-746.
82. Bartels EM, Lund H, Hagen KB, Dagfinrud H, Christensen R, Danneskiold- Samsøe B. Aquatic exercise for the treatment of knee and hip osteoarthritis. Cochrane Database Syst Rev. 2007;(4):CD005523.
83. Focht BC. Effectiveness of exercise interventions in reducing pain symptoms among older adults with knee osteoarthritis: a review. J Aging Phys Act. 2006;14(2):212-235.
84. Snibbe JC, Gambardella RA. Treatment options for osteoarthritis. Oththopedics. 2005;28(2 suppl):S215-S220.
85. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3-9.
86. Divine JG, Zazulak BT, Hewett TE. Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res. 2007;455:113-122.
87. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33(5):946-950.
88. Huin-Amargier C, Marchal P, Payan E, Netter P, Dellacherie E. New physically and chemically crosslinked hyaluronate (HA)-based hydrogels for cartilage repair. J Biomed Mater Res A. 200676(2): 416-424.
89. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum. 1967; 10(4):357-376.
90. Gomis A. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 2004;50:314-326.
91. Weiss C, Band P. Basic principles underlying the development of viscosupplementation for the treatment of osteoarthritis. J Clin Rheumatol. 1999;5(6suppl):S2-S11.
92. Waddell DD. Viscosupplements affect on IL-1 mediated MMP activity. Clin Orihop Rel Res. 2007;465:241-248.
93. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a meta-analysis of randomized controlled trials. J Bone Joint Surg. 2004;86-A: 538-545.
94. Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. 2009;3 7(8): 1636-1644.
95. Williams NH, Amoakwa E, Burton K, et al. The Hip and Knee Book: developing an active management booklet for hip and knee osteoarthritis. Br J Gen Pract. 2010;60(571):64-82.
96. Jackson DW, Evans NA, Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg. 2002; 84-A(9): 1522-1527.
97. Langworthy MJ. A review of the first 100 office Synvysc One injections. Physician Rev. 2008;(suppl):A1-A6.
98. Mathieu P, Conrozier T, Vignon E, Rozand Y, Rinaudo M. Rheologic behavior of osteoarthritic synovial fluid after addition of hyaluronic acid: a pilot study. Clin Orihop Relat Res. 2009;467(11):3002-3009.
99. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis ofthe knee. American College of Rheumatology. Arthritis Rheum. 1995;38(11): 1541-1546.
100. Raynauld JP, Torrance GW, Band PA, et al; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F-20 into the treatment paradigm with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002; 10(7): 506-517.
101. Caligaris M, Canal CE, Ahmad CS, Gardner TR, Ateshian GA. Investigation of the frictional response of osteoarthritic human tibiofemoral joints and the potential beneficial tribological effect of healthy synovial fluid. Osteoarthritis Cartilage. 2009;17(10):1327-1332.
102. Doherty M, Dieppe P. The "placebo" response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage. 2009; 17(10): 1255-1262.